Toward risk-adjusted CT schedules in first-line metastatic colorectal cancer

In an era of precision oncology, the follow-up of metastatic colorectal cancer (mCRC) presents a paradox: while treatment is increasingly tailored to molecular subtypes, monitoring for progression still follows a uniform, one-size-fits-all schedule. The entrenched 2- to 3-month restaging interval is a convention rooted more in habit than in evidence. This rigid timetable overlooks the substantial heterogeneity of mCRC, leading…